What does this research mean for the field?

Acquired resistance to EGFR- and ALK-targeted therapies in non-small cell lung cancer is driven by diverse molecular mechanisms that necessitate adaptive molecular monitoring and customized therapeutic strategies to maximize long-term outcomes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To delineate the molecular drivers of acquired resistance to EGFR and ALK inhibitors in non-small cell lung cancer and evaluate emerging diagnostic biomarkers and counter-therapeutic strategies.

September 5, 2026CureusOpen Access

Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies

View Full Paper

Ask AI

Bookmark

To delineate the molecular drivers of acquired resistance to EGFR and ALK inhibitors in non-small cell lung cancer and evaluate emerging diagnostic biomarkers and counter-therapeutic strategies.
Synthesized molecular mechanisms underlying acquired resistance to targeted tyrosine kinase inhibitors in EGFR- and ALK-altered non-small cell lung cancer.
Evaluated advanced diagnostic tools for monitoring resistance, including circulating tumor DNA, exosomes, multi-omics, and artificial intelligence prediction models.
Reviewed pipeline therapeutic strategies and clinical trials, including fourth-generation inhibitors, antibody-drug conjugates, and bispecific antibodies.
Target resistance arises through secondary on-target kinase mutations, bypass signaling activation, epithelial-mesenchymal transition, tumor heterogeneity, and microenvironment alterations.
Liquid biopsies and circulating tumor DNA allow early detection of resistant sub-clones before radiographic disease progression occurs.
Emerging therapies under investigation to overcome resistance include fourth-generation kinase inhibitors, antibody-drug conjugates, bispecific antibodies, and adaptive combination regimens.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review outlines resistance mechanisms to targeted therapies in EGFR- and ALK-mutated non-small cell lung cancer, highlighting novel biomarkers and combination strategies to improve survival.

Cite This Study

Dhillon et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd3c76b95aff0620eaeca https://doi.org/10.7759/cureus.115685

View Full Paper

Ask AI

Bookmark

Implication

Review outlines resistance mechanisms to targeted therapies in EGFR- and ALK-mutated non-small cell lung cancer, highlighting novel biomarkers and combination strategies to improve survival.

Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies

Key Points

Discussion

Implication

Cite This Study

Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider